Constitutive expression of cyclin D1 is a frequent abnormality in human cancer and sustains the transformed phenotype. We have previously demonstrated that cyclin D1 is constitutively expressed in human BON neuroendocrine tumour cells due to an autocrine insulinlike growth factor-I (IGF-I) loop. Here we examine the regulation of cyclin D1 expression by endogenously released IGF-I in BON cells. Cyclin D1 expression in these cells was found to be dependent on phosphatidylinositol 3-kinase (PI3-K), but independent of the extracellular signal-regulated kinase cascade. Ras-and RacGTPases were found to be upstream activators of cyclin D1 expression, whereas protein kinase B/AKT and nuclear factor kappa B (NFjB) could be established as downstream mediators of cyclin D1 transcription in response to endogenously released IGF-I in these cells. In addition, the Ras/PI3-K/AKT/Rac/NFjB/cyclin D1 signaling cascade triggered by endogenously released IGF-I is sufficient to sustain Rb phosphorylation and cdk4 kinase activity in BON cells. In conclusion, our data provide the first comprehensive map of the signaling events elicited by endogenously released IGF-I leading to constitutive cyclin D1 expression in human neuroendocrine tumour cells.
Results and discussion
Carcinoid tumours are rare neoplasms derived from neuroectodermal cells and predominantly found in the gastrointestinal tract. Some of these tumours exhibit a high proliferative capacity that correlates with the expression of cyclin D1 (Oberg, 2002) . BON cells have been established from a human pancreatic carcinoid tumour and are a well-established model to study the biology of human neuroendocrine tumours in vitro (Evers et al., 1994) . We have demonstrated that cyclin D1 is constitutively expressed in BON cells. This process is largely regulated by an autocrine insulin-like growth factor-I (IGF-I) loop, which appears to be present in many neuroendocrine tumours (von Wichert et al., 2000) .
The cyclin D1 protein is the regulatory subunit of a holoenzyme. Its catalytic subunits, cdk4 or cdk6, phosphorylate and inactivate the tumour suppressor Rb (retinoblastoma protein) (Sherr, 1996) . The abundance of the cyclin D1 gene product is a rate-limiting step in G1 phase progression. Cyclin D1 mRNA levels are rapidly induced during G1 phase progression and cyclin D1 is actively degraded upon withdrawal of growth factors. Constitutive expression of cyclin D1 is one of the most frequent abnormalities in human cancer leading to enhanced cell transformation and tumorigenesis (Weinstein, 2000) . Consequently, inhibition of cyclin D1 expression reverts the malignant phenotype of cancer cells (Zhou et al., 1995; Arber et al., 1997) . The precise mechanisms responsible for constitutive cyclin D1 expression in tumours are not fully understood and likely to be cell-type specific. Here, we identify the signaling mechanisms mediating the sustained cyclin D1 expression in human BON neuroendocrine tumour cells.
The autocrine IGF-I loop stimulates multiple signaling pathways in BON cells including activation of phosphatidylinositol 3-kinase (PI3-K) and the extracellular signal-regulated kinase (ERK) cascade (von Wichert et al., 2000) . To determine the IGF-I dependent pathways mediating cyclin D1 expression, BON cells were incubated with an IGF-I immunoneutralizing antibody (IGF-IN-Ab), PD 98059 or Ly 294002 for various times to inhibit the autocrine IGF-I loop, PI3-K activity, and the mitogen-activated protein kinase kinase (MEK)/ERK cascade, respectively. Cell lysates were further analysed by Western blotting with antibodies directed against cyclin D1, cyclin D3, cyclin E and p27 kip1 . Ly 294002 and PD 98059 blocked the constitutive activation of PI3-K and ERKs, respectively, in BON cells (Figure 1a ). Cyclin D1 expression was markedly reduced when cells were incubated with the IGF-IN-Ab for 48 h (Figure 1 ). The antibody had no effect on the expression of cyclin D3 and cyclin E and even increased the expression of p27 kip1 . A very similar effect was observed when cells were incubated with Ly 294002. In contrast, treatment of cells with PD 98059 had no effect on the expression levels of cyclin D1, cyclin D3, cyclin E and p27 kip1 (Figure 1 ). Thus, PI3-K, and not the ERK cascade, regulates expression of cyclin D1 and p27 kip1 in BON cells. To determine the role of potential downstream targets of PI3-K we examined the expression and activity of AKT in BON cells. AKT was found to be constitutively phosphorylated in BON cells (Figure 1b (Figure 1b) , demonstrating that the PI3-K/AKT pathway mediates cyclin D1 expression induced by the autocine IGF-I loop in Bon cells.
Next, we were interested in the regulatory mechanisms at the level of cyclin D1 gene transcription. BON cells were treated for 48 h with IGF-I, Ly 294002, PD 98059, the IGF-IN-Ab or an unspecific monoclonal anti-Tyr(P) antibody, respectively. Cyclin D1 mRNA expression was subsequently quantified by RT-PCR. Treatment of the cells with the PI3-K inhibitor and the IGF-IN-Ab reduced basal cyclin D1 mRNA expression by about 50% (Figure 2a ). In contrast, the MEK inhibitor reduced basal cyclin D1 mRNA expression only slightly. Treatment of BON cells with IGF-I did not result in a further increase in cyclin D1 mRNA expression, suggesting that the endogenously released IGF-I already stimulates maximum cyclin D1 expression.
PI3-K has been implicated in growth factor-induced cyclin D1 promoter/reporter gene activity (Guillemot et al., 2000) . To examine directly the signaling pathways stimulating cyclin D1 promoter activity, BON cells were transfected with a cyclin D1 reporter construct containing the full-length wild-type promoter. As shown in Figure 2b , the high basal activity of the cyclin D1 promoter in BON cells was inhibited in the presence of Ly 294002 or the IGF-IN-Ab. In contrast, incubation of cells with a nonspecific monoclonal antibody or the MEK inhibitor PD 98059 had no effect on the transcriptional activation of cyclin D1. These data were confirmed by coexpressing the cyclin D1 reporter construct with an expression plasmid containing a dominant-negative acting MEK mutant (dnMEK), a dominant-negative acting p110 subunit of PI3-K (p110Dk) or a dominant-negative acting AKT construct (dnAKT). Cotransfection of the dnMEK construct had no effect on the activity of the cyclin D1 promoter in BON cells. However, growth factor-induced activation of a Drosphila E74 reporter plasmid, a downstream target of the ERK cascade, was abolished by cotransfecting the dnMEK construct or by incubation with PD 98059 (data not shown). Upon cotransfection of the cyclin D1 reporter with the p110Dk mutant, basal cyclin D1 transcriptional activity was virtually abolished. This effect is mediated via AKT since cotransfection of a dominant-negative AKT construct markedly reduced cyclin D1 reporter activity and this effect was not further enhanced in the presence of LY 294002 (Figure 2c ). Thus, transcriptional activation of cyclin D1 in BON cells is largely regulated by autocrine IGF-I via PI3-K and AKT.
There are several potential upstream regulators of PI3-K that could mediate IGF-I-induced cyclin D1 reporter activity in BON cells including Ras (Downward, 1997) . Indeed, IGF-I activates Ras in BON cells (data not shown). Coexpression of constitutively active V12ras and the cyclin D1 reporter in BON cells resulted in a 3.8-fold increase in cyclin D1 transcriptional activity. This activation was inhibited by 50% after (Figure 2d , left). This suggests that in BON cells, maximum activation of the cyclin D1 promoter by constitutively active Ras is mediated by PI3-K and, to a lesser degree, by ERKs. Coexpression of a dominantnegative acting N17ras plasmid and the cyclin D1 reporter resulted in a 70% reduction in cyclin D1 promoter activity, which was not further reduced by the additional treatment of cells with Ly 294002 or PD 98059 (Figure 2d , right). Thus, Ras is a major upstream regulator of PI3-K-stimulated cyclin D1 transcription in response to endogenously released IGF-I in BON cells. The GTPase Rac can also be activated by IGF-I (Cheng et al., 2000) . Rac can act downstream of Ras and upstream as well as downstream of PI3-K (Gille and Downward, 1999) . In addition, Rac is a potential regulator of cyclin D1 promoter activity (Page et al., 1999; Zahir et al., 2003) . Coexpression of the cyclin D1 reporter and dominant-negative N17Rac inhibited activity of the cyclin D1 reporter by 60%, suggesting that Rac is another upstream regulator of cyclin D1 transcription in BON cells. Interestingly, the activity of the cyclin D1 reporter was even further decreased in the presence of both N17Rac and Ly 294002, suggesting that Rac is not the major upstream regulator of PI3-K in BON cells. The combination of PD 98059 and N17Rac 0 . PCR reactions were performed in duplicate for each sample using the primer combinations listed below (Sybr Green PCR Core Reagents, PE Applied Biosystems) and normalized to the endogenous cyclophilin mRNA level for each reaction. The primer concentration was 300 nM in all experiments. Results are the means7s.e. of three independent experiments. (b) Cyclin D1 transcriptional activity is dependent on endogenously released IGF-I and PI3-K. BON cells were transfected with a cyclin D1 reporter plasmid carrying the firefly luciferase gene using Fugene (Roche) according to the manufacturer's instructions. At 24 h after transfection, cells were incubated with 25 mg/ml IGF-I-IN-Ab (IGF-IN-Ab), 25 mg/ml monoclonal anti-Tyr (P) antibody (uAb), 20 mM Ly 294002 (Ly), 15 mM PD 98059 (PD) or 100 ng/ml IGF-I for further 48 h. Control cells received an equivalent amount of solvent (À). Cells were lysed and luciferase activity in equal amounts of protein was determined by luminometry (Lumat LB 9501; EG&G Berthold). Data are the means7s.e. of five independent experiments. (c) BON cells were cotransfected with the cyclin D1 reporter plasmid and a dominant-negative acting MEK expression plasmid (dnMEK, þ ; right), a dominant-negative acting p110 subunit of PI3-K (p110Dk, þ ; middle), or a dominant-negative acting AKT-(dnAKT, þ ; left) or vector (À) using Fugene. At 24 h after transfection, cells were incubated with 20 mM Ly 294002 (Ly, þ ) or 15 mM PD 98059 (PD, þ ) for 48 h. Cells were lysed and luciferase activity in equal amounts of protein was determined by luminometry. Similar results were obtained in Dual-Luciferase reporter assays after correction for Renilla luciferase activity (data not shown). Data are the means7s.e. of three independent experiments. (d) Ras stimulates cyclin D1 transcription in BON cells by a PI3-K-and MEK-dependent signaling pathway. BON cells were cotransfected with the cyclin D1 reporter plasmid and a constitutively active V12ras expression construct (V12ras, þ ; left) or a dominant-negative acting ras expression plasmid (N17ras, þ ; right) or vector (À) using Fugene. At 24 h after transfection, cells were incubated with 20 mM Ly 294002 (Ly, þ ) or 15 mM PD 98059 (PD, þ ) for 48 h. Cells were lysed and luciferase activity was determined in equal amounts of protein by luminometry. Data are expressed as fold increase above control luciferase activity (left) or as % inhibition of maximum luciferase activity detected in control cells (right) and are the means7s.e. of at least three independent experiments. (e) Rac but not RhoA activates cyclin D1 transcription in BON cells. Cells were cotransfected with the cyclin D1 reporter plasmid and a dominant-negative rac expression plasmid (N17rac, þ ; left) or a dominant-negative rhoA expression plasmid (N19rhoA, þ ; right) or vector (À) using Fugene. At 24 h after transfection, cells were incubated with 20 mM Ly 294002 (Ly, þ ) or 15 mM PD 98059 (PD, þ ) for 48 h. Control cells received an equivalent amount of solvent (À). Cells were lysed and luciferase activity was determined in equal amounts of protein by luminometry. Data are the means7s.e. of at least three independent experiments Regulation of cyclin D1 by endogenous IGF-I G von Wichert et al had no additional inhibitory effect on cyclin D1 transcriptional activity (Figure 2e, left) . Therefore, Rac activity is required for cyclin D1 promoter activity in BON cells and Rac is likely to be downstream or sidestream of PI-3-K in the IGF-I signaling pathway leading to cyclin D1 transcriptional activity. Coexpression of the cyclin D1 reporter and dominant-negative N19RhoA had no effect on transcriptional activation of the cyclin D1 reporter (Figure 2e, right) . This demonstrates that Ras and Rac, but not RhoA, are involved in the regulation of cyclin D1 expression by endogenously released IGF-I in BON cells. Next, we were interested in the transcriptional regulators downstream of PI3-K mediating IGF-Istimulated cyclin D1 promoter activity in BON cells. The cyclin D1 promoter contains multiple cis-elements including binding sites for AP-1 and nuclear factor kappa B (NFkB) (Albanese et al., 1995; Joyce et al., 2001) . To determine the potential effect of endogenously released IGF-I on transcriptional activation of NFkB and AP-1, BON cells were transfected with reporter plasmids containing a promoter composed of either three NFkB-or six AP-1 binding DNA consensus sites, linked to a luciferase reporter gene. Exogenously added IGF-I induced a two-fold increase in the activity of the NFkB-and the AP-1 reporter, respectively. Basal activity of the NFkB reporter was markedly decreased in BON cells treated with the IGF-IN-Ab. A similar decrease in NFkB reporter activity was observed upon treatment of cells with Ly 294002 (Figure 3a , left). PD 98059 had no effect on the basal NFkB reporter activity. AP-1 reporter activity was also markedly reduced by treatment of BON cells with the IGF-IN-Ab or with Ly 294002, but also by PD 98059 (Figure 3a, right) . Thus, endogenously released IGF-I is sufficient to trigger the activation of a NFkB-1 as well as an AP-1 reporter plasmid in BON cells and PI3-K mediates the activation of both reporters. The MEK-ERK cascade is only required for the activation of AP-1 in BON cells.
To substantiate these findings we examined the effect of the IGF-IN-Ab on NFkB-and AP-1 DNA binding activity by electrophoretic mobility shift assays (EMSAs). Nuclear extracts from serum-starved BON cells pretreated with the IGF-IN-Ab or with solvent were subjected to EMSAs employing DNA probes that represented NFkB-or AP-1 binding motifs. In control nuclear extracts we observed constitutive, specific binding of labeled oligonucleotides representing the NFkB-or AP-1 binding site (Figure 3b , left and right), which was further enhanced by treatment of cells with IGF-I. Upon incubation of the cells with the IGF-INAb, NFkB-and AP-1 DNA binding activities were markedly decreased, virtually to the same level as in samples that were competed by a molar excess of wild type, cold NFkB-or AP-1 probe, respectively (Figure 3b) . A comparable decrease in NFkB-or AP-1 DNA binding activity was observed by incubation of the cells with the selective NFkB inhibitor SN 50 (Lin et al., 1995) or PD 98059, respectively. The inhibitors were selective: PD 98059 had no effect on NFkB DNA binding activity and SN 50 did not affect AP-1 DNA Figure 3 Endogenously released IGF-I activates the DNA binding activity of NFkB and AP-1 (a) BON cells were cotransfected with a NFkB-(left) or an AP-1 reporter plasmid both carrying the firefly luciferase gene (right). At 24 h after transfection, cells were incubated with 100 ng/ml IGF-I, 20 mM Ly 294002 (Ly) or 15 mM PD 98059 (PD) or 25 mg/ml IGF-I-IN-Ab (Ab) for 48 h. Cells were subsequently lysed and luciferase activity was determined in equal amounts of protein by luminometry. Data are the means7s.e. of at least three independent experiments. (b) Serum-starved BON cells were incubated with 25 mg/ml IGF-I-INAb (Ab), 20 mM Ly 294002 (Ly), 15 mM PD 98059 (PD), 100 ng/ml IGF-I or 20 mM SN 50 for 48 h. Cells were lysed and NFkB-(top) and AP-1-DNA binding activities (bottom) were determined by EMSA using NFkB-and AP-1-specific oligonucleotides (Promega Corp). To show the specificity of the bands, a 100 Â molar excess of the unlabeled respective oligonucleotide (cCO) was used for competition. The arrows indicate the position of the NFkB-or AP-1-specific DNA binding activity and the position of a nonspecific (n.s.) activity. (c) BON cells were cotransfected with either reporter plasmids for cyclin D1 (Cyclin D1), AP-1 (AP-1), or NFkB (NFkB) and a dominant-negative acting Fos expression plasmid (DFos) or empty vector (À). At 24 h after transfection, cells were incubated with 20 mM SN 50 (Biomol). Cells were lysed and luciferase activity was determined in equal amounts of protein by luminometry. Data are the means7s.e. of at least three independent experiments Regulation of cyclin D1 by endogenous IGF-I G von Wichert et al binding activity. Treatment of cells with the PI3-K inhibitor Ly 294002 prevented both NFkB-and AP-1-DNA binding activity to the same degree as the IGF-IN-Ab. Thus, the autocrine IGF-I loop regulates activation of both NFkB-and AP-1-DNA binding activity via PI3-K in BON cells, whereas the MEK-ERK signaling pathway is only required for the AP-1 DNA binding activity. These data are in good agreement with the data obtained in the NFkB-and AP-1 reporter assays.
Next, we examined whether transcriptional activation of cyclin D1 was dependent on AP-1 activity. Jun:Fos and Jun:ATF complexes represent two classes of AP-1 dimers that preferentially bind to either heptameric or octameric AP-1 binding sites. To examine whether Jun:Fos complexes would play a role in the regulation of cyclin D1 promoter activity in BON cells, a dominant-negative acting fos plasmid (DFos) was coexpressed with the cyclin D1 reporter plasmid in BON cells. Coexpression of DFos and the cyclin D1 reporter did not interfere with cyclin D1 transcriptional activation. However, coexpression of DFos and the AP-1 reporter markedly reduced AP-1 reporter activity (Figure 3c ). The selective NFkB inhibitor SN 50 markedly reduced basal cyclin D1 and NFkB transcriptional activation but had no effect on AP-1 reporter activity in BON cells (Figure 3c and data not shown). Thus, endogenously released IGF-I stimulates transcriptional activation of cyclin D1 in BON cells via a Ras/ PI3-K/Rac/NF-kB dependent signaling pathway and is largely independent of the MEK-ERK cascade and AP-1 activity.
To establish whether the constitutive expression of cyclin D1 was functionally relevant, we determined the activity of the cyclin D1-cdk4 holoenzyme in BON cells using a GST-Rb fusion protein as substrate. As shown in Figure 4a , serum-starved BON cells exhibit a high level of basal cdk4 activity. Addition of IGF-I only slightly further enhanced cdk4 activity. Incubation of the cells with the IGF-IN-Ab or with Ly 294002 led to a marked reduction in cdk4 activity. In accordance with our previous data, incubation of BON cells with PD 98059 had no effect on cdk4 activity. Furthermore, as expected, there was no distinct band when no GST-Rb fusion protein was added as substrate (data not shown). Thus, the constitutive cyclin D1 expression is sufficient to activate the cyclin D1-cdk4 holoenzyme by a PI3-Kdependent pathway in BON cells. To establish that this cdk4 activity was sufficient to trigger phosphorylation of endogenous Rb, we performed Rb mobility shift assays. Indeed, Rb was constitutively phosphorylated in serumstarved BON cells as demonstrated by a retarded electrophoretic mobility in SDS-PAGE. Phosphorylation of Rb was only slightly enhanced by stimulation of the cells with exogenously added IGF-I. Incubation of the cells with the IGF-IN-Ab or Ly 294002 markedly reduced the constitutive Rb phosphorylation whereas PD 98059 had no effect on Rb phosphorylation.
The data presented above reveal the signaling mechanisms regulating constitutive cyclin D1 expression in response to endogenously released IGF-I in an in vitro model of human neuroendocrine tumours, the BON cells. They point to a major role of PI3-K as a regulator of cyclin D1 transcriptional activity in these cells. The MEK-ERK pathway, which is crucial for cyclin D1 transcription, for example, in response to EGF or a5b1 integrins (Albanese et al., 1995; Lavoie et al., 1996; Roovers et al., 1999) , is not involved in the regulation of cyclin D1 expression by autocrine IGF-I in BON cells. The regulation of cyclin D1 expression is likely to be cell type specific: cyclin D1 induction by exogenously added IGF-I is largely dependent on ERK activation in myoblasts (Coolican et al., 1997) and IGF-I dependent proliferation and cyclin D1 expression in intestinal smooth muscle cells requires the activation of both, the ERK cascade and the PI3-K signalling pathway (Kuemmerle et al., 2004) . However, our data suggest that in human BON neuroendocrine tumour cells, the ERK cascade is not involved in the regulation of NF-kB activity and cyclin D1 expression by endogenously released IGF-I, which is in contrast to other cell types. In addition, we identified Ras and Rac as activators of cyclin D1 transcriptional activity in response to , 25 mg/ml IGF-I-IN-Ab (Ab) or 100 ng/ml IGF-I for 48 h. Cells were subsequently lysed in 50 mM HEPES, pH 7.5, 1 mM EDTA, 2.5 mM EGTA, 1 mM DTT, 250 mM NaCl, 10% glycerol, 0.1% Tween 20, 1 mM NaF, 0.1 mM Na 3 VO 4 , and protease inhibitors (aprotinin 10 mg/ml, leupeptin 10 mg/ml, 1 mM AEBSF) for 1 h on ice. The lysates were subsequently immunoprecipitated using a monoclonal anti-cdk4 antibody (Upstate Biotech) and cdk4 activity was determined by an in vitro kinase assay using a GST-Rb fusion protein (AA 773-923; Upstate Biotech (Zahir et al., 2003) . Furthermore, our data show that in human neuroendocrine tumour cells AKT is likely to act downstream of PI3-K in the control of cell cycle progression. Despite the fact that AP-1 transcription factors activate the cyclin D1 promoter, cyclin D1 promoter activity in response to endogenously released IGF-I is largely independent of AP-1 activity, but crucially dependent on NFkB activity in BON cells. Importantly, the level of constitutive cyclin D1 expression in BON cells is sufficient to trigger cdk4 activity and Rb phosphorylation. We establish a Ras/PI3-K/ AKT/Rac/NFkB signaling cascade, which is activated by endogenously released IGF-I and leads to the activation of cyclin D1 transcriptional activity, constitutive cyclin D1 protein expression and hence constitutive activation of the cyclin D1-cdk4 holoenzyme in BON neuroendocrine tumour cells. Constitutive nuclear cyclin D1 expression is not limited to the BON cell model. We observed a similar constitutive nuclear expression of cyclin D1 in various human neuroendocrine tumours (v Wichert G and Seufferlein T, unpublished observations). Thus, this cascade could be a novel target for the treatment of these tumours.
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